RNA technologies have taken the world by storm over the pandemic and now the potential to of RNA engineering to enhance cell therapy is finally being realized.

The therapeutic potential of RNA cell therapies is huge, but challenges remain in cell-specific delivery, improving durability of responses, demonstrating safety and elucidating regulatory considerations to deliver for patients.

The inaugural RNA Cell Therapy Summit is the first of its kind to unite 80+ industry and academic pioneers from both the RNA and cell therapy field to bridge-the-gap between transient RNA engineering and cell therapy development.

Join industry trailblazers at BioNTech, Sanofi, Intellia, Editas, Capstan and more to future-proof your pipeline with the pinnacle of cell engineering to develop the next-generation of safer, more functional and scalable cell therapies through the clinic.

URLs:
Tickets: https://go.evvnt.com/1322042-2?pid=1052
Brochure: https://go.evvnt.com/1322042-3?pid=1052

Prices:
Conference + 2 Workshops - Drug Developer : USD 4297.00,
Conference + 1 Workshop - Drug Developer: USD 3648.00,
Conference Only - Drug Developer: USD 2999.00,
Conference + 2 Workshops - Academic: USD 3697.00,
Conference + 1 Workshop - Academic: USD 3148.00,
Conference Only - Academic: USD 2599.00,
Conference + 2 Workshops - Service Provider : USD 5097.00,
Conference + 1 Workshop - Service Provider: USD 4348.00,
Conference Only - Service Provider: USD 3599.00

Speakers: Shizuka Uchida | Professor and Co- Director, Center for RNA Medicine | Department of Clinical Medicine Aalborg University, Haig Aghanjanian | Co-Founder and Vice President of Research | Capstan Therapeutics, Michael Singer | Chief Scientific Officer | Cartesian Therapeutics, Milos Miljkovic | Chief Medical Officer | Cartesian Therapeutics, Emily English | Senior Director of Quality | Cartesian Therapeutics, John Zuris | Director, Editing Technologies | Editas Medicine, Gregory Fiore | Chief Executive Officer | Exacis Biotherapeutics, Aaron Prodeus | Associate Director, Cell Engineering | Intellia Therapeutics, Birgit Schultes | Senior Vice President, Cell Therapies | Intellia Therapeutics, David Peritt | Founder and Chief Scientific Officer | Lupagen, Hamideh Parhiz | Research Assistant Professor of Medicine | Perelman School of Medicine, University of Pennsylvania, Artavazd Arumov | Associate | Qiming Venture Partners, Dan Shores | Partner | Rothwell Figg, Jonathan Gilbert | Vice President Exploratory Research | SQZ Biotechnologies, Victor Levitsky | Chief Scientific Officer | Targovax, Thomas Birkballe Hansen | Vice President of Research | Targovax, Dharini Shah | Senior Research Director, Immunology | Tidal (a Sanofi Company), Robert Mabry | Chief Scientific Officer | Orna Therapeutics, Tania Chakrabarty | Director, Analytical Chemistry | Sana Biotechnology, Pierre Côte | Head of Strategic Partnerships and innovation Management mRNA Center of Excellence | Sanofi